BillionToOne Raises 2026 Revenue Guidance
The diagnostics company lifted its full-year outlook after third-quarter revenue grew 47% year over year.
Updated on Nov. 15, 2026 in Biotech

BillionToOne raised its full-year 2026 revenue guidance to between $460 million and $470 million during its third quarter earnings call on November 4, 2026. Total revenue grew 47% year over year to $123 million, with gross margin reaching 71%.
Why it matters
The company reported its fifth consecutive quarter of positive GAAP operating income, a profitability milestone for a company in the diagnostics sector. Higher average selling prices and growing oncology volume drove the results, and management believes it can sustain the current margin profile as oncology grows into a larger share of the business.
The figures come from BillionToOne's own third quarter 2026 earnings report, showing $123 million in revenue up 47% year over year and a $169 cost per test. The extraction does not specify how the company's gross margin or revenue guidance compares with prior periods or industry benchmarks.
The players
BillionToOne
BillionToOne is a diagnostics company focused on oncology testing, including the Northstar Response and Northstar Clear products.
The details
BillionToOne held its third quarter 2026 earnings call on November 4, 2026, reporting that Northstar Response matched or beat a leading tissue-dependent test in a published head-to-head study for monitoring treatment response. The company also plans to launch Northstar Clear on December 15, 2026, a blood-draw test that avoids physical tumor tissue samples.
Timeline
November 4, 2026: BillionToOne holds its third quarter 2026 earnings call.
December 15, 2026: Planned commercial launch of Northstar Clear.
The Tech Race
BillionToOne's Northstar Response matched or beat a leading tissue-dependent test in a published head-to-head study, and the planned Northstar Clear launch extends that approach to a blood-draw format. The shift away from physical tissue samples positions the company against incumbent tissue-based oncology diagnostics.
Patients and oncologists considering treatment-response monitoring may eventually have a blood-draw option that avoids physical tumor tissue samples. The December 15, 2026 Northstar Clear launch date is the practical milestone for availability.
The takeaway
Removing the need for physical tissue samples can eliminate processing delays in cancer treatment monitoring. The growth of BillionToOne's oncology volume and its profitability signal a company scaling this approach.
What happens next
BillionToOne plans to launch Northstar Clear on December 15, 2026.
Further reading
Explore more Biotech developments shaping oncology diagnostics in the United States.









